Zenas BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 20, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Cap	1,279	1,978	342	-	-
Market Cap Growth	321.02%	477.98%	-	-	-
Enterprise Value	937.29	1,635	-8.26	0	0
Last Close Price	22.30	36.31	8.19	-	-
PE Ratio	-	-4.30	-0.69	-	-
PS Ratio	127.92	197.84	68.46	-	-
PB Ratio	5.02	8.17	1.10	-	-
P/TBV Ratio	4.12	6.71	0.35	-	-
P/FCF Ratio	-	-11.48	-2.86	-	-
P/OCF Ratio	-	-11.48	-2.86	-	-
EV/Sales Ratio	93.73	163.54	-1.65	-	-
EV/EBITDA Ratio	-	-4.27	0.05	-	-
EV/EBIT Ratio	-	-4.27	0.05	-	-
EV/FCF Ratio	-	-9.49	0.07	-	-
Debt / Equity Ratio	0.00	0.00	0.00	0.01	0.02
Debt / EBITDA Ratio	0.00	0.00	-0.01	-0.02	-0.02
Debt / FCF Ratio	-0.01	-0.01	-0.01	-0.03	-0.02
Net Debt / Equity Ratio	-1.41	-1.41	-1.12	0.25	0.34
Net Debt / EBITDA Ratio	0.89	0.89	2.14	1.51	0.86
Net Debt / FCF Ratio	1.98	1.98	2.92	1.84	1.00
Asset Turnover	0.03	0.03	0.02	0.70	0
Quick Ratio	5.48	5.48	6.12	2.44	2.59
Current Ratio	5.61	5.61	6.21	2.57	2.64
Return on Equity (ROE)	-136.22%	-136.22%	-93.22%	-101.22%	-249.54%
Return on Assets (ROA)	-101.64%	-101.64%	-75.01%	-51.62%	-102.17%
Return on Invested Capital (ROIC)	1311.77%	1311.77%	675.12%	251.83%	426.12%
Return on Capital Employed (ROCE)	-120.90%	-120.90%	-91.66%	-79.43%	-156.75%
Earnings Yield	-29.53%	-23.24%	-145.18%	-	-
FCF Yield	-13.47%	-8.71%	-35.00%	-	-
Buyback Yield / Dilution	-7.73%	-7.73%	-70.38%	-	-

Updated Mar 16, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q